For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Vyndamax and Attruby represents a significant change. These groundbreaking therapies protect the transthyretin protein, halting its harmful build-up and alleviating the impact of the illness. Patients are now experiencing positive ou